<DOC>
	<DOCNO>NCT00722332</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics , safety efficacy HepaGam B combination antiviral therapy prevention hepatitis B virus ( HBV ) recurrence follow HBV-related orthotopic liver transplant .</brief_summary>
	<brief_title>Evaluation HepaGam BÂ® Combination With Antiviral Treatment Hepatitis B Liver Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Written inform consent HBsAgpositive candidate HBVrelated liver transplant Treatment antiviral therapy transplantation per treat physician 's recommendation . ( NOTE : It expect patient receive Lamivudine Adefovir Dipivoxil pretransplant . In case antiviral resistance , effective alternative antiviral agent ( ) must use . ) Multiorgan transplantation recipient Liver retransplantation except primary nonfunction Presence hepatoma ( large 5.0 cm solitary node ) 2 3 multifocal node ( large 3.0 cm ) ( Milan Criteria ) base information available baseline visit ( CT scan , MRI ) . Patients require OLT ( Orthotopic Liver Transplant ) due fulminant hepatitis B OLT patient receive liver graft donor positive HBsAg Patients use interferon pretransplant ( interferon use posttransplant ) History IgA ( immunoglobulin A ) deficiency History hypersensitivity blood product . HIV HCV positive Use investigational product , participation another clinical trial course study ( exception qualityoflife repository study ) Pregnancy plan pregnancy course study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>HBIG ( Hepatitis B Immune Globulin )</keyword>
	<keyword>Chronic Hepatitis B Recurrence</keyword>
	<keyword>Liver Transplant</keyword>
</DOC>